Global market for acute heart failure (AHF) drugs

DUBLIN, March 1, 2024 (Globe Newswire) — The Acute Heart Failure (AHF) Therapeutics: Global Strategic Business Report report has been added. ResearchAndMarkets.com Recruitment.

Global acute heart failure (AHF) drug market expected to reach $2.9 billion by 2030

The global market for acute heart failure (AHF) therapeutics is estimated to be USD 599.7 million in 2022, and is projected to reach a revised size of USD 2.9 billion by 2030, with a projected growth in 2022-2030. growing at a CAGR of 21.7% over the analysis period of 2018.

Cardiac glycosides, one of the segments analyzed in the report, is projected to register a CAGR of 22.3% and reach USD 762.4 million by the end of the analysis period. Taking into account the continued recovery post-pandemic, the growth of the B blocker division is recalibrated such that his CAGR for the next eight years is revised to his 25.1%.

The acute heart failure (AHF) market has been significantly impacted by the coronavirus disease (COVID-19) pandemic and the looming global recession. Despite challenges, diuretics and vasodilators remain first-line treatment for AHF, but the efficacy of other known agents for AHF is limited, preventing their widespread use. .

Market insights and trajectories present a complex picture influenced by these factors, with varying degrees of competitive market presence seen among players across the globe in 2022. Recent market activity reflects continued efforts to expand the size of the AHF market and adapt to the evolving medical landscape. Future market outlook suggests a continued focus on addressing the challenges posed by COVID-19 and economic uncertainty, while exploring opportunities for innovation and growth in AHF therapeutics.

The US market is estimated at $163.4 million, while China is projected to grow at a CAGR of 30.4%

The US acute heart failure (AHF) therapeutics market is estimated to be USD 163.4 million in 2022. China, the world’s second largest economy, is expected to reach a projected market size of USD 841.2 million by 2030, following a CAGR. In the analysis period 2022-2030, it was 30.4%.

story continues

Other notable geographic markets include Japan and Canada, which are expected to grow by 16.3% and 18.4%, respectively, between 2022 and 2030. Among Europe, Germany is projected to grow at a CAGR of approximately 17.1%. The Asia-Pacific market is expected to reach USD 433.4 million by 2030, led by countries such as Australia, India, and South Korea.

Key attributes:

Market overview

• Insights into the influencer market

• Global market trajectory

• market outlook

• Recent market activity

• Determining the size of the AHF market

• Acute heart failure – disease overview and available treatments

• Diuretics and vasodilators – first-line treatment for AHF

• Other known drugs for AHF – low efficacy precludes use

• Acute Heart Failure (AHF) Treatments – Market Share Percentage of Major Global Competitors in 2022 (E)

• Competitive Market Presence – Strong/Active/Niche/Mediocre (E) for Players Worldwide in 2022

• The impact of the new coronavirus infection (Covid-19) and the looming global recession

Market trends and drivers

• Traditional treatments leave significant unmet need

• A novel treatment that brings a ray of hope

• Key AHF treatments in the pipeline

• Serelaxin approaches RELAX-AHF-2 trial results

• Uraritide – a new drug under development for AHF

• As the number of drug failures increases, the importance of prevention increases.

• Other promising drugs in development

• research result

• Renal insufficiency – predictor of acute heart failure

• Genetic influences on heart disease in African Americans

• Elevated BMI – an important risk factor for AHF

• Supplemental oxygen therapy is not applicable to all cases of AHF

• Drivers of macro growth

• Alarming levels of cardiovascular disease (CVD) prevalence: a key growth driver for AHF therapeutics

• The rapidly growing elderly population: a key growth driver for AHF treatment

Focus on carefully selected players (Total of 93 items posted)

• Bayer AG (Germany)

• Bristol-Myers Squibb Company (USA)

• Cardiorentis AG (Switzerland)

• CVie Therapeutics Limited (Taiwan)

• Cytokinetics (USA)

• Merck & Co. (USA)

• Novartis AG (Switzerland)

• Orion Co., Ltd. (Finland)

• PhaseBio Pharmaceuticals, Inc. (USA)

For more information on this report, please visit https://www.researchandmarkets.com/r/rdba26.

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.

attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900